I. U. Haq

发表

Robustness measures for integrated structural/control systems

Ramana V. Grandhi, Rama K. Yedavalli, I. U. Haq, 1990 .

Implications of recent trials with lipid-lowering drugs for hypertension management

I. U. Haq, L. Ramsay, P. Jackson, 1996 .

4.3 The impact of ambulatory blood pressure on estimation of cardiovascular risk in mild hypertension

I. U. Haq, L. Ramsay, P. Jackson, 1997 .

Prediction of coronary risk for primary prevention of coronary heart disease: a comparison of methods.

I. U. Haq, L. Ramsay, P R Jackson, 1999, QJM : monthly journal of the Association of Physicians.

The effects of dietary change on serum cholesterol

I. U. Haq, L. Ramsay, L. Ramsay, 1995, Proceedings of the Nutrition Society.

Coronary and cardiovascular risk estimation for primary prevention:validation of a new Sheffield table in the 1995 Scottish health survey population

I. U. Haq, P. Ghahramani, L. Ramsay, 2000, BMJ : British Medical Journal.

Oily fish and fish oil supplements in the prevention of coronary heart disease

I. U. Haq, L. Ramsay, P. Jackson, 1998 .

Use of risk scores in anticoagulation

I. U. Haq, B. Bawamia, Yaasir Mamoojee, 2012, BMJ.

Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease

I. U. Haq, L. Ramsay, P. Jackson, 1995, The Lancet.

I. U. Haq, L. Ramsay, P. Jackson, 1997, BMJ.

Coronary events with lipid-lowering therapy: the AFCAPS/TexCAPS trial. Air Force/Texas Coronary Atherosclerosis Prevention Study.

I. U. Haq, L. Ramsay, P. Jackson, 1999, JAMA.

Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease

I. U. Haq, A. Simon, J. Levenson, 1995, The Lancet.

Statins for primary prevention: at what coronary risk is safety assured?

I. U. Haq, L. Ramsay, P. Jackson, 2001, British journal of clinical pharmacology.

Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management.

I. U. Haq, L. Ramsay, L. Ramsay, 1999, Journal of hypertension.

Is coronary risk an accurate surrogate for cardiovascular risk for treatment decisions in mild hypertension? A population validation

I. U. Haq, P. Ghahramani, L. Ramsay, 2001, Journal of hypertension.

Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men

I. U. Haq, I. Haq, L. Ramsay, 1999, Heart.

Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment

I. U. Haq, C. McCabe, L. Ramsay, 1999, Heart.

Should cholesterol be measured in all hypertensives?

I. U. Haq, L. Ramsay, P. Jackson, 1995, Journal of human hypertension.